Tellgen Corp Total Liabilities

Latest as of June 2026: CN¥538.19 Million CNY ≈ $78.75 Million USD

Tellgen Corp total liabilities. Based on the latest financial reports, Tellgen Corp (300642) has total liabilities worth CN¥538.19 Million CNY (≈ $78.75 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Tellgen Corp asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Tellgen Corp (2012–2025)

Total liabilities of Tellgen Corp from 2012 to 2025. This chart illustrates how Tellgen Corp's total liabilities have evolved over time, based on quarterly financial data.

Tellgen Corp Competitors by Total Liabilities

The table below lists competitors of Tellgen Corp ranked by their total liabilities.

Company Country Total Liabilities
Daodaoquan Grain and Oil Co Ltd
SHE:002852
China CN¥2.19 Billion
Beijing HuaYuanYiTong Thermal Technology Co Ltd
SHE:002893
China CN¥1.19 Billion
Xunlei Ltd Adr
NASDAQ:XNET
USA $234.06 Million
Rechi Precision Co Ltd
TW:4532
Taiwan NT$16.14 Billion
Ascencio (D)
BR:ASCE
Belgium €367.49 Million
Pharmicell
KO:005690
Korea ₩19.60 Billion
Eg Industries Bhd
KLSE:8907
Malaysia RM1.33 Billion
Hotel Majestic Cannes
PA:MLHMC
France €33.61 Million

Liability Composition Analysis (2012–2025)

This chart breaks down Tellgen Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Tellgen Corp's balance sheet.

Liquidity & Leverage Metrics

Tellgen Corp Total Liabilities Ratios Explained

Tellgen Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 6.68 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.37 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.27 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Tellgen Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Tellgen Corp (2012–2025)

The table below shows the annual total liabilities of Tellgen Corp from 2012 to 2025.

Year Total Liabilities Change
2025-12-31 CN¥576.38 Million
≈ $84.34 Million
+149.57%
2024-12-31 CN¥230.94 Million
≈ $33.79 Million
+60.33%
2023-12-31 CN¥144.05 Million
≈ $21.08 Million
-21.74%
2022-12-31 CN¥184.07 Million
≈ $26.94 Million
+79.43%
2021-12-31 CN¥102.59 Million
≈ $15.01 Million
-2.48%
2020-12-31 CN¥105.19 Million
≈ $15.39 Million
+35.13%
2019-12-31 CN¥77.84 Million
≈ $11.39 Million
-1.07%
2018-12-31 CN¥78.68 Million
≈ $11.51 Million
+100.17%
2017-12-31 CN¥39.31 Million
≈ $5.75 Million
-24.23%
2016-12-31 CN¥51.88 Million
≈ $7.59 Million
+34.84%
2015-12-31 CN¥38.47 Million
≈ $5.63 Million
+25.22%
2014-12-31 CN¥30.72 Million
≈ $4.50 Million
-6.56%
2013-12-31 CN¥32.88 Million
≈ $4.81 Million
+270.61%
2012-12-31 CN¥8.87 Million
≈ $1.30 Million
--

About Tellgen Corp

SHE:300642 China Medical Devices
Market Cap
$362.12 Million
CN¥2.47 Billion CNY
Market Cap Rank
#13587 Global
#3991 in China
Share Price
CN¥15.25
Change (1 day)
-5.22%
52-Week Range
CN¥11.22 - CN¥22.54
All Time High
CN¥46.24
About

Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; tumor methylation; cardiovascular, eugenics, and inflammation. It also provides diagnostic reagents/testing instruments and assembly lines. The company was founded in… Read more